Exicure (XCUR) Competitors $8.99 -0.35 (-3.75%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. GOSS, RNAC, INZY, LFCR, NGNE, PRTA, OCGN, AMRN, AARD, and MDWDShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Gossamer Bio (GOSS), Cartesian Therapeutics (RNAC), Inozyme Pharma (INZY), Lifecore Biomedical (LFCR), Neurogene (NGNE), Prothena (PRTA), Ocugen (OCGN), Amarin (AMRN), Aardvark Therapeutics (AARD), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Its Competitors Gossamer Bio Cartesian Therapeutics Inozyme Pharma Lifecore Biomedical Neurogene Prothena Ocugen Amarin Aardvark Therapeutics MediWound Exicure (NASDAQ:XCUR) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership. Do institutionals & insiders believe in XCUR or GOSS? 42.8% of Exicure shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 3.9% of Exicure shares are held by company insiders. Comparatively, 6.7% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is XCUR or GOSS more profitable? Gossamer Bio's return on equity of -127.28% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -190.90% -36.75% Gossamer Bio N/A -127.28%-22.12% Does the MarketBeat Community favor XCUR or GOSS? Gossamer Bio received 148 more outperform votes than Exicure when rated by MarketBeat users. Likewise, 67.09% of users gave Gossamer Bio an outperform vote while only 47.37% of users gave Exicure an outperform vote. CompanyUnderperformOutperformExicureOutperform Votes947.37% Underperform Votes1052.63% Gossamer BioOutperform Votes15767.09% Underperform Votes7732.91% Which has more risk & volatility, XCUR or GOSS? Exicure has a beta of 3.71, suggesting that its share price is 271% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Do analysts rate XCUR or GOSS? Gossamer Bio has a consensus price target of $7.75, suggesting a potential upside of 507.84%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, XCUR or GOSS? Exicure has higher earnings, but lower revenue than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K113.60-$16.91M-$4.81-1.87Gossamer Bio$124.59M2.33-$179.82M-$0.23-5.54 Does the media prefer XCUR or GOSS? In the previous week, Gossamer Bio had 7 more articles in the media than Exicure. MarketBeat recorded 8 mentions for Gossamer Bio and 1 mentions for Exicure. Exicure's average media sentiment score of 1.89 beat Gossamer Bio's score of 1.17 indicating that Exicure is being referred to more favorably in the media. Company Overall Sentiment Exicure Very Positive Gossamer Bio Positive SummaryGossamer Bio beats Exicure on 13 of the 17 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.80M$6.91B$5.61B$8.54BDividend YieldN/A2.54%5.28%4.17%P/E Ratio-4.348.6027.1819.77Price / Sales113.60261.11411.66152.70Price / CashN/A65.8538.3234.64Price / Book5.146.556.984.63Net Income-$16.91M$143.75M$3.24B$248.14M7 Day Performance-16.76%-0.70%-0.29%-0.46%1 Month Performance-21.14%10.44%8.48%4.16%1 Year Performance2,581.98%3.13%32.16%13.35% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure1.8071 of 5 stars$8.99-3.7%N/A+2,330.4%$56.80M$500K-4.3450Positive NewsUpcoming EarningsGap DownGOSSGossamer Bio3.8252 of 5 stars$1.16+4.1%$7.75+571.0%+144.0%$262.53M$124.59M-3.61180Positive NewsAnalyst RevisionRNACCartesian Therapeutics1.8875 of 5 stars$9.98+4.4%$43.00+330.9%-65.6%$259.02M$34.17M-0.1964Positive NewsAnalyst RevisionGap DownINZYInozyme Pharma3.2003 of 5 stars$3.97flat$11.75+196.0%-20.4%$256.31MN/A-2.5450High Trading VolumeLFCRLifecore Biomedical1.9592 of 5 stars$6.87+1.5%$8.00+16.4%+25.6%$254.36M$130.31M-12.27690NGNENeurogene3.529 of 5 stars$17.75+4.4%$44.60+151.3%-45.1%$253.15M$925K-4.0890News CoverageAnalyst ForecastGap DownPRTAProthena3.8221 of 5 stars$4.66+1.5%$31.50+576.0%-76.4%$250.83M$137.94M-2.03130Positive NewsShort Interest ↓Analyst RevisionHigh Trading VolumeOCGNOcugen1.5451 of 5 stars$0.84+0.1%$6.00+616.7%-22.1%$244.49M$4.52M-4.6580Positive NewsGap DownAMRNAmarin0.5401 of 5 stars$11.74+1.3%$7.00-40.4%-17.7%$243.10M$214.11M-130.44360Gap DownAARDAardvark TherapeuticsN/A$11.13+6.6%$31.25+180.8%N/A$241.48MN/A0.0018News CoverageAnalyst RevisionGap DownMDWDMediWound2.0843 of 5 stars$22.24+1.3%$31.80+43.0%+26.6%$240.37M$19.21M-7.6780 Related Companies and Tools Related Companies Gossamer Bio Alternatives Cartesian Therapeutics Alternatives Inozyme Pharma Alternatives Lifecore Biomedical Alternatives Neurogene Alternatives Prothena Alternatives Ocugen Alternatives Amarin Alternatives Aardvark Therapeutics Alternatives MediWound Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XCUR Stock Free XCUR Stock Alerts